Chelsie Derman

Phase 3 HAELO data show significant reductions in attack rates and treatment burden with a single-dose in vivo CRISPR therapy; BLA submission underway with FDA.

Phase 2 RAPIDe-1 trial shows an oral bradykinin B2 antagonist improves symptom relief and reduces rescue therapy use in hereditary angioedema attacks.

FDA updates, phase 3 CRISPR data in HAE, and emerging food allergy prevention strategies defined allergy and immunology news in April 2026.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).

A study presented at the ATS 2026 found the New York City Housing Authority's Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.